Key Takeaways
- Volume-led 35% YoY revenue jump: Q3 revenue hit ₹201.83 crores, driven by healthier demand and stronger volumes, even as pricing volatility persisted across product categories.
- Margins held despite low plant utilization: 9-month EBITDA margin of 17.06% was achieved with the Pakhajan facility running at just 40–45% utilization, supported by product mix refinement and cost discipline.
- A landmark MNC supply agreement is fully funded and underway: A unique molecule, unique process deal is customer-funded (₹85–90 crores capex), with commercialization targeted for Q1 FY28 and discussions active with other majors for similar arrangements.
- Tariffs forced a diversification that management now frames as a structural positive: The 50% US tariff hit was real but limited in exposure, and it pushed Yasho into South America, Africa, and new Asian markets it had previously ignored.
- What to watch next quarter: Whether the two new manufacturing lines begin trial runs on schedule in March 2026, any quantification of FY27 revenue when budgeting concludes, and the trajectory of Pakhajan utilization from its current sub-50% level.
The MNC Strategic Project: A Customer-Funded Growth Anchor
- Deal structure is rare for the industry: A large MNC is fully funding ₹85–90 crores in capex for a dedicated manufacturing line, with ₹19.9 crores advance already received, because the molecule and process are unique and Yasho had the specific capability to execute.
- Timeline is specific and back-end loaded: Equipment deliveries begin Q2 FY27, trial runs and commissioning follow, and commercialization is targeted for Q1 FY28, meaning revenue contribution is an FY28 story.
- More such deals are in discussion: Management is working with all major players in rubber and lubricant fields for similar long-term supply agreements, though details remain under NDA and no further disclosures will come before commercial production starts.
- The customer's rationale is capability, not cost: Management acknowledged it does not know the customer's internal mindset on funding capex, but the selection rested on Yasho being able to handle a unique molecule with a unique process.
Parag Jhaveri: "I don't know much on that, what is the customer mindset. But I can say this is a very unique molecule, has a unique process. So that's -- and we had a capability to manage that kind of thing. So that's why customer has chosen Yasho as the partner, long-term partner."
Capacity Build-Out and the FY28 Revenue Ambition
- Two new manufacturing lines are nearing trial runs: ₹25.9 crores deployed toward lines focused on high-visibility product categories with sustained demand; trial runs expected March 2026 and commercial production Q1 FY27.
- The ₹1,500 crore FY28 target is a utilization potential, not a commitment: Management clarified under analyst pushback that the figure represents the potential to achieve roughly 80% utilization of available Pakhajan capacity with existing capex, the LTSA revenue stream, and debottlenecking, not a firm guidance.
- The facility is built for a long growth runway: Infrastructure already supports 15–25% annual growth over the long term, and management expects a 4:1 revenue-to-capex ratio on incremental investments.
- Optimal utilization is an FY28 event: Pakhajan utilization, currently at 40–45%, is expected to reach 80–85% only by FY28, with peak revenue from the facility in the ₹750–850 crore range depending on market conditions.
- Contract mix aspiration tilts toward stability: At full utilization, management aspires to have 60–70% of revenue under long-term contracts and 30% in the spot market.
Parag Jhaveri: "I can say Manish bhai that's the potential to achieve the 80% utilization of the Yasho capacity."
Tariffs, Diversification, and the US Recovery Bet
- Tariff damage was contained by limited exposure: The 50% US tariff on some products had a substantial negative impact on sales and margins where it applied, but Yasho had very limited business on those specific products, while products with exemptions saw business continuity.
- Diversification is the silver lining management emphasizes: The tariff shock pushed Yasho into South America, Africa, and Asian markets where it was previously not active, with product mix being churned specifically for these new geographies.
- US recovery is expected as tariffs recede: With the tariff "almost on the way out," management expects reasonable growth back in the US market, where share was previously more than 30–35% and is expected to be regained.
- Europe is a parallel opportunity with a timing caveat: The India-EU free trade agreement brings chemicals to 0%, but implementation timing is uncertain; customer response from Europe is described as very positive, and two Europe-based salespeople came on board in the last six months.
Parag Jhaveri: "Well, that would have been substantial sales if the tariff would not be there, also the margin could have been better. But I say basically as well, the tariff has helped us to look beyond comfort market... that is helping us to diversify our portfolio."
Margin Mechanics and the Utilization Lever
- Blended margin guidance is 17–19%: Management expects to achieve an additional 1–1.5% margin as plant utilization improves from current depressed levels, with the full benefit tied to the Pakhajan ramp toward 80–85% by FY28.
- Gross margin compression is a mix story, not a pricing collapse: 80% of the gross margin change in industrial products is explained by product mix shift, with the remaining 20% from volume-linked discounts for bulk buyers; the company strategically sold lower-margin products based on customer demand.
- Inventory build-up is deliberate, not a demand miss: Stock was built because the plant must operate at certain efficiency levels, and the build was based on visibility of future orders.
- Working capital is tightening: Tighter inventory practices, better receivable collections, and production cycles synchronized with order visibility are reducing working capital intensity, with further improvement expected in Q4.
- Debt reduction is the central financial priority: Gross debt levels are expected to stabilize next quarter, with the focus on lowering the debt-to-EBITDA multiple through improved profitability, controlled capex, and strong cash generation; long-term debt will reduce while short-term debt may not increase from current levels.
Competitive Landscape and the China Question
- A Chinese competitor is expanding in the lube additive space: Management is aware and says it is well-prepared, but acknowledges it will be "a bit of tough competition" and declined to divulge further strategic details.
- R&D is targeting revenue-scale molecules and new applications: The R&D center at Pakhajan is looking for molecules generating at least ₹25 crore revenue per year, and exploring applications beyond rubber and lubricants; the Performance Chemicals segment is growing at a healthy speed with multiple projects on similar chemistry, different chemistry, and altogether new areas.
- Domestic market growth is a bright spot: Strong growth over the last two quarters has been driven by identifying new markets, increased customer reach with aggressive pricing, and improving demand across both industrial and consumer segments, led by lubricants and rubber additives.
- Industrial mix is set to rise further: The industrial segment is expected to shift from 85–90% of revenue to 90–95% over the next two years, while the consumer segment remains flat or degrows further.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New manufacturing lines trial runs | Trial runs to begin | March 2026 |
| New manufacturing lines commercial production | Commercial production to start | Q1 FY27 |
| MNC project equipment deliveries | Equipment deliveries to begin | Q2 FY27 |
| MNC project commercialization | Commercial production targeted | Q1 FY28 |
| Pakhajan optimal utilization | Reach 80–85% utilization | By FY28 |
| Blended EBITDA margin | 17–19%, with 1–1.5% additional from improved utilization | Sustained; utilization-dependent |
| Revenue-to-capex ratio | 4:1 on incremental investments | Ongoing |
| Debt reduction | Stabilize gross debt; reduce debt-to-EBITDA multiple | Next quarter and ongoing |
| US market recovery | Regain 30–35%+ share as tariffs recede | Tariff-dependent; timing unstated |
| Industrial segment mix | Shift from 85–90% to 90–95% of revenue | Next 2 years |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹201.83 cr, +35% YoY |
| 9M revenue | ₹583.76 cr, +19% YoY |
| EBITDA margin | 16.65%, driven by sourcing efficiencies and operational discipline |
| 9M EBITDA margin | 17.06% |
| FY26 full-year revenue expectation | ~₹800 cr |
| FY28 revenue potential | ~₹1,500 cr, at ~40% utilization of Pakhajan facility |
| FY28 margin guidance | 17% to 19% |
| Americas revenue share | 20% to 22% of total revenue |
| Industrial segment sales share | 85% to 90%, expected to reach 90% to 95% in next 2 years |
| Pakhajan capacity utilization | 40% to 45%, dropped below 50% since Q2 |
| Days of inventory | ~170 days (raw material, finished goods, work in process) |
| Gross borrowings | ~₹560 cr (bank loans ~₹500 cr, promoter loans ~₹50 cr) |
| Capex deployed in FY26 | ~₹55 to 60 cr (₹25 cr for two manufacturing lines, ₹25 cr for R&D) |
| MNC project cost | ₹85 to 90 cr, fully customer-funded; advance of ₹19.9 cr received |
| Long-term contract vs spot mix at full utilization | 60% to 70% long-term contracts, 30% spot |